Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Saxagliptin

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus

• HbA1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months)

• High risk for CV events -Established cardiovascular disease and/or multiple risk factors

Exclusion Criteria:

• Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics

• Acute vascular event <2months prior to randomisation